EKSO Earnings

EKSO reported its FY2025Q3 earnings on 2025-10-28, showcasing a revenue of 4.23M against an estimate of 4.16M, resulting in a 1.7% surprise. The EPS was -0.54, surpassing the expected -0.99 by 45.45%. The stock experienced a 9.15% price change on the earnings day and a 7.28% change over the next five days, reflecting market reactions to the results.

Following EKSO's FY2025Q3 earnings announcement on 2025-10-28, the stock price moved by 9.15% on the day of the release. Over the subsequent five days, it saw a 7.28% change. Historically, EKSO's stock price tends to shift by an average of -0.36% in the 10 days leading up to earnings and -8.12% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate EKSO's annual revenue to reach 4.55M, while the EPS is projected at -0.43. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between EKSO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EKSO's stock price typically moves by -0.36% in the 10 days before its earnings and -8.12% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.43 and revenue of 4.55M.

The earnings call highlighted several negative factors: a significant revenue decline, reduced gross profit and margins, and an increased net loss. The Q&A revealed deferred sales due to regulatory issues and uncertainty in Enterprise Health sales recovery. Despite some progress in the Indego Personal business and cost management efforts, the challenges in coding, coverage, and payment processes, alongside supply chain risks and AI integration uncertainties, contribute to a negative sentiment. The lack of clear guidance on grant reliance further exacerbates concerns, likely leading to a negative stock price reaction.